Skip to main content
OpenTrials
Completed

NCT Number: NCT06810947

Evaluation of Treatments for Allergic Rhinitis (Rhinal 2)

The goal of this clinical study is to perform a post-market clinical follow-up of 2 medical devices (liquid bandage in the form of a spray : ALLERSPRAY G (product A - code AAG), PCNS (product B - code PC) indicated for symptomatic treatment of allergic rhinitis. This follow-up will consist in collecting real-life clinical data to confirm the safety and efficacy of medical devices used in the treatment of allergic rhinitis of adults patients while allowing an assessment of the product's risk/benefit ratio.

The main questions it aims to answer are:

* Primary objective : Evaluate in real life the tolerance of medical device A and B used in the treatment of allergic rhinitis. * Secondary objectives : Evaluate the efficacy of medical device A and B on allergic rhinitis and the quality of life using the device A and B.

No comparison group will be constituated because of the type of study (post market follow up) and no comparison between device A and B will be done.

58 participants (29 for medical device A and 29 for medical device B) with allergic rhinitis will be asked to :

* use medical device A or B during 2 weeks (from inclusion visit to end of study visit), * complete each day at home a diary (recording intensity of 4 nasal symptoms, adverse events, concomitant treatments), * complete " Quality of life evaluation (sleep, daily activities, fatigue, irritability) " at inclusion visit and end of study visit.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Allergic Rhinitis Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Nose Diseases Otorhinolaryngologic Diseases Respiratory Hypersensitivity Respiratory Tract Diseases Rhinitis Rhinitis, Allergic

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

CHU Clermont-Ferrand

Clermont-Ferrand, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • " Score For Allergic Rhinitis " ≥ 8
  • Age ≥ 18
  • Able to refrain from using any treatment for allergic rhinitis or any other treatment that could interfere with the purpose of the study,
  • Effective contraception for women of reproductive age,
  • Cooperation and understanding sufficient to comply with the requirements of the study,
  • Acceptance to give written consent and inscription to VRB french platform for the duration of the study,
  • Affiliation to the French Social Security system,

Exclusion criteria

  • Known hypersensitivity to any of the components of the evaluated products,
  • Use of any treatment to treat allergic rhinitis,
  • pregnant or breastfeeding women,
  • participating in another clinical trial, or being in the exclusion period, or having received a total amount of benefits exceeding EUR 6000 over the 12 months preceding the start of the trial,
  • benefiting from a measure of legal protection (guardianship, deprivation of liberty, safeguard of justice),
  • having a medical and / or surgical history judged by the investigator or his representative to be incompatible with the test

Treatment and study plan

ALLERSPRAY-G (device A)

Device

Symptomatic treatment consists of 3 sprays of medical device A in each nostril while breathing in slightly. This process should be repeated 4 times a day for 14 days by patients participating in the study.

PCNS (device B)

Device

Symptomatic treatment consists of 3 sprays of medical device B in each nostril while breathing in slightly. This process should be repeated 4 times a day for 14 days by patients participating in the study.

Primary outcomes

  1. Adverse events

    Time frame: From visit 1 (day 1) to the end of treatment at day 14

    Recording of all adverse events on an electronic journal

Secondary outcomes

  1. Total nasal symptom score (TNSS)

    Time frame: basal and twice a day from visit 1 (day 1) to the end of treatment at day 14

    4 symptoms (stuffy nose, runny nose, sneezing, itching nose) will be evaluated (from 0 "no embarassement" to 10 "extremely embarrassed") by the patient every day during the treatment period (from day 1 to day 14). the 4 symptoms composed the total nasal symptom score (TNSS). Basal and the mean last 3 days of treatment TNSS score of will be compared.

  2. Impact of allergic rhinitis on sleep

    Time frame: basal (day 1) and after the study treatment period (day 15)

    Evaluation of how much your allergic rhinitis and associated symptoms interfere/impact on sleep (from 0 (not annoying/not at all impact) and 10 (extremely annoying/very impacted) on a visual analog scale

  3. Impact of allergic rhinitis on daily activities

    Time frame: basal (day 1) and after the study treatment period (day 15)

    Evaluation of how much your allergic rhinitis and associated symptoms interfere/impact on daily activities (from 0 (not annoying/not at all impact) and 10 (extremely annoying/very impacted) on a visual analog scale

  4. Impact of allergic rhinitis on fatigue

    Time frame: basal (day 1) and after the study treatment period (day 15)

    Evaluation of how much your allergic rhinitis and associated symptoms interfere/impact on fatigue (from 0 (not annoying/not at all impact) and 10 (extremely annoying/very impacted) on a visual analog scale

  5. Impact of allergic rhinitis on irritability

    Time frame: basal (day 1) and after the study treatment period (day 15)

    Evaluation of how much your allergic rhinitis and associated symptoms interfere/impact on irritability (from 0 (not annoying/not at all impact) and 10 (extremely annoying/very impacted) on a visual analog scale

Sponsors and collaborators

Lead sponsor

University Hospital, Clermont-Ferrand

Other

Collaborators

  • Vitrobio

Registry information

Official study title

Evaluation of Treatments for Allergic Rhinitis

Acronym: RHINAL 2

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Feb 6, 2025
Registry last updated
Jun 13, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.